Telix Pharmaceuticals (OTCMKTS:TLPPF) Shares Down 2.2% – Time to Sell?

Telix Pharmaceuticals Limited (OTCMKTS:TLPPF)’s share price traded down 2.2% during trading on Friday . The stock traded as low as $6.55 and last traded at $6.8450. 5,071 shares changed hands during trading, an increase of 39% from the average session volume of 3,661 shares. The stock had previously closed at $7.00.

Telix Pharmaceuticals Stock Down 2.2%

The business has a 50 day moving average price of $7.97 and a two-hundred day moving average price of $9.58.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals is a molecularly targeted radiopharmaceutical company specializing in the development and commercialisation of diagnostic and therapeutic products for oncology and rare diseases. The company leverages radioisotopes conjugated to disease-specific targeting agents, enabling precise imaging and treatment of cancerous lesions. Telix’s portfolio includes investigational imaging compounds, such as a gallium-68-labeled prostate cancer agent, alongside therapeutic candidates that deliver beta- or alpha-emitting isotopes directly to disease sites.

Telix’s lead diagnostic program focuses on positron emission tomography (PET) imaging for prostate cancer, designed to improve detection and staging accuracy.